logo
Dogs and cats can also suffer from allergies, but there are ways to help our furry friends

Dogs and cats can also suffer from allergies, but there are ways to help our furry friends

CTV News31-05-2025
Dr. Karen Woodard check's Gail Friedman's dog, Ms. Roxie, for signs of allergies in Elmhurst, Ill. on May 13, 2025. (AP Photo/Laura Bargfeld)
About five years ago, Gail Friedman noticed her Parson Russell Terrier was constantly licking his paws and seemed super uncomfortable.
'The poor dog. I would put baby socks on his feet so that he wouldn't lick them or bite at them,' said Friedman, of Oak Brook, Illinois. 'I was constantly changing the socks, washing his feet a lot. Nothing worked.'
It turned out her canine companion, Mr. Friedman, had allergies.
It's a common and tricky problem in pets — caused by various things such as pollen, dust, mold, chemicals and food — but veterinarians say there are several ways to ease their suffering.
What sorts of allergies do dogs and cats get?
Allergies happen when the immune system overreacts to a foreign substance. Cats and dogs react to many of the same things people do, as well as pests like fleas.
There are no definitive recent statistics on how many pets have allergies, but research suggests the problem is growing.
'I probably see allergic dogs and cats every single day, probably multiple times a day,' said Dr. Karen Woodard, medical director at Thrive Pet Healthcare-Elmhurst in Illinois.
About 90 per cent of allergic pets react to environmental triggers, Woodard said, and the rest have food allergies only.
Dog breeds that are especially vulnerable include various types of terriers, boxers and bulldogs; in cats, it's Persians, Siamese and Himalayans.
Pets can even be allergic to other animals — cats to dogs, dogs to cats and either to another species.
'It's possible for them to be allergic to us, just like we are to them,' said Thrive's Dr. Anthea Elliott Schick of Scottsdale, Arizona, immediate past president of the American College of Veterinary Dermatology.
How can you tell if your pet has allergies?
Allergic cats and dogs aren't as likely as humans to sneeze and cough. More often, they scratch and lick themselves, shake their heads and develop ear infections.
Woodard said her Yorkie mix, Teddy, had the classic signs — scratching around his shoulders and getting rashes and ear infections starting as a six-month-old puppy. She lived in the South at the time, and he tested positive for allergies to various trees and grasses there.
A common sign of allergies in her feline patients is 'overdoing their grooming,' said Woodard, who's on the Chicago Veterinary Medical Association's board of directors. 'Cats shouldn't be pulling their hair out when they groom. So if you start seeing bald patches on your cat, even though the skin underneath it looks normal, that could be a sign of allergies.'
Even food allergies, often to chicken, beef, lamb or other protein sources, frequently show up on the skin, although pets can have vomiting or diarrhea, too.
Rarely, pets can develop life-threatening anaphylactic reactions, perhaps after being stung by an insect. But most allergies are simply miserable for the animals.
'It breaks my heart because it gets to a point that not only do I have socks on poor Mr. Friedman — which is humiliating for him — he sometimes gets so bad he has to wear the cone of shame,' Gail Friedman said. 'And that's not fair because he can't move around right, he can't sleep right. It's terrible.'
How can you help your pet?
The first step is to get a diagnosis from the vet. This could involve allergy testing, or in the case of food allergies, an 'elimination diet,' which involves feeding limited ingredients the pet hasn't previously eaten.
If the allergy culprit is environmental, there are medications like anti-inflammatory drugs and newer oral and injectable medications for dogs to block chemical signals associated with itchiness. Food allergies may be treated with special diets such as 'hydrolyzed' food, in which proteins are chemically broken down into tiny pieces.
All this can get expensive. Friedman estimates she's spent about US$10,000 on testing, medication and care for Mr. Friedman and another allergic dog.
But vets say there are also ways to help pets at home by cleaning their bedding frequently, wiping their fur with a wet washcloth and giving them baths.
Outdoors, 'they're almost acting like little Swiffers, getting allergens on their skin, and it goes through their skin and actually becomes a problem,' Schick said. 'We say bathe your dog, at a minimum, once a week if they're allergic.'
After she's tried nearly everything, Friedman's dogs are still vexed by allergies. But they're doing better.
'I'm going to keep experimenting until we find what stops it completely,' she said. 'All you can do is try.'
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Laura Ungar, The Associated Press
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Viking Therapeutics Stock Zoomed 5% Higher Today
Why Viking Therapeutics Stock Zoomed 5% Higher Today

Globe and Mail

time2 hours ago

  • Globe and Mail

Why Viking Therapeutics Stock Zoomed 5% Higher Today

Key Points Good news from a peer and a positive analyst update were the elements driving Viking Therapeutics (NASDAQ: VKTX) stock higher on the first trading day of the week. The clinical-stage biotech, closely watched by some because of its investigational weight-loss drug VK2735, saw its share price improve by more than 5% as a result. By contrast, the S&P 500 index basically traded flat across the trading session. What's good for the goose... The news driving Viking and other obesity drug developers came from a leading company in that space, Wegovy maker Novo Nordisk. Late Friday, the Denmark-based pharmaceutical announced that Wegovy earned approval from the U.S. Food and Drug Administration (FDA) to treat a new indication, noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), a liver disorder. Companies like Viking and Novo Nordisk have been on the radar of many of an investor because of the obvious side benefits to obesity drugs. The latter company earning a fresh approval to treat a medical issue besides obesity provides a significant morale boost to shareholders of weight loss drug developers. Bullish stance reiterated Also improving sentiment on Viking stock was that new analyst note. Monday morning before market open, Piper Sandler 's Biren Amin reiterated his overweight (buy, in other words) recommendation and $71-per-share price target on the biotech. Amin's focus, according to reports, wasn't Novo Nordisk's recent news; rather, he was cheered by the prospects for VK2735. Viking is putting an oral version of the medication through clinical trials, and the readout of a phase 3 study is expected within this calendar quarter. In his estimation, if oral VK2735 continues to do well in testing and is brought to market, it could garner sales of $2.1 billion. Should you invest $1,000 in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025

Buy, Hold, or Fade the Recent Rally in UnitedHealth Group (UNH) Stock?
Buy, Hold, or Fade the Recent Rally in UnitedHealth Group (UNH) Stock?

Globe and Mail

time7 hours ago

  • Globe and Mail

Buy, Hold, or Fade the Recent Rally in UnitedHealth Group (UNH) Stock?

UnitedHealth Group UNH stock is still down 40% year to date but has surged more than +20% this month following reports that Warren Buffett's Berkshire Hathaway BRK.B and other billionaire hedge fund managers have taken a stake in the company, including David Tepper's Appaloosa Management. In a classic value investing move, Buffett undoubtedly sees long-term value in UnitedHealth Group as a high-quality business at a steep discount, investing in other industry leaders during a crisis like Goldman Sachs GS during the 2008 financial meltdown and more recently Occidental Petroleum OXY during the Covid-19 pandemic plunge in energy prices. To that point, UnitedHealth has faced a DOJ investigation stemming from its health services and technology subsidiary Optum, and had previously suspended its full-year financial guidance due to unexpectedly high medical costs. Considering such, investors may be weighing the pros and cons of investing in UNH, with some wondering if it's time to fade the recent rally. UnitedHealth's Attractive Valuation & Balance Sheet As the parent company of United Healthcare, the nation's largest insurer, UnitedHealth Group stock had recently fallen toward its decade low in terms of price to forward earnings and is still on par with its 10-year foward P/E median of 18X. Furthermore, UNH trades at less than 1X sales and has the scale, diversification, and cash flow that are likely attracting Buffett and other large investors to believe in its long-term recovery. Notably, UnitedHealth Group has more than $32 billion in cash and equivalents on hand and over $308 billion in total assets compared to $208.1 billion in total liabilities. UNH EPS Revisions Despite reinstating its guidance, UnitedHealth Group now expects full-year fiscal 2025 EPS to be considerably lower at a least $16 per share, with the Zacks Consensus currently at $16.58 and falling 25% over the last 60 days from expectations of $22.28. While the drop in FY25 EPS estimates was expected, what may be more concerning to investors is that FY26 EPS estimates have dropped nearly 30% in the last two months from projections of $25.58 to $18.08. Conclusion & Final Thoughts The institutional pile into UnitedHealth Group stock may have set a psychological floor for investors, but the trend of declining EPS revisions does take away from the company's enticing valuation and suggests there could still be much better buying opportunities ahead. Correlating with such, it may be time to fade the recent rally, with UNH landing a Zacks Rank #5 (Strong Sell) at the moment. For investors who may be interested in limiting the short-term risk associated with the recent volatility in UnitedHealth Group stock, Zacks analyst Sanghamitra Saha has alluded to the notion that the iShares U.S. Healthcare Providers ETF IHF could be a better way to get exposure to UNH. Free Report: Profiting from the 2nd Wave of AI Explosion The next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives. Investors who bought shares like Nvidia at the right time have had a shot at huge gains. But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies. Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI's next leap forward. Access AI Boom 2.0 now, absolutely free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report The Goldman Sachs Group, Inc. (GS): Free Stock Analysis Report Occidental Petroleum Corporation (OXY): Free Stock Analysis Report Berkshire Hathaway Inc. (BRK.B): Free Stock Analysis Report iShares U.S. Healthcare Providers ETF (IHF): ETF Research Reports

U.S. patients can now get Ozempic for half price if they can pay cash
U.S. patients can now get Ozempic for half price if they can pay cash

CTV News

time11 hours ago

  • CTV News

U.S. patients can now get Ozempic for half price if they can pay cash

Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for US$499, for those who pay for medications on their own and don't go through insurance. The move comes as U.S. President Donald Trump is pressuring drugmakers to lower drug costs, which have long been a major health care headache for Americans. He and lawmakers have called out popular but pricey GLP-1 drugs, which are used for diabetes and weight loss, noting they are much more expensive in the United States than in other countries. Trump has also been pushing pharmaceutical manufacturers to provide medications directly to consumers at a lower price, cutting out insurers and other players. Novo Nordisk is making Ozempic, which carries a list price of just under $1,000 per month, available at its NovoCare Pharmacy, which ships medications directly to cash-paying consumers. The drugmaker earlier this year launched the direct-to-consumer pharmacy, offering Wegovy, its in-demand weight loss drug, for $499 a month. Rival Eli Lilly has also slashed the price of its GLP-1 weight loss drug, Zepbound, for self-pay patients. The discounted Ozempic price is also available on other platforms, including Novo Nordisk's website and through a partnership with GoodRx, which offers discounts on prescriptions at many pharmacies. The offer is open to eligible patients with an Ozempic prescription, the drugmaker said. Insurers are more likely to cover Ozempic for those with diabetes than they are Wegovy, and Novo Nordisk offers discounts for those with coverage. However, Novo Nordisk is looking to broaden Ozempic's availability even further. 'While Ozempic is well covered in the US, let's not forget that there are some patients who pay out-of-pocket for this vital medicine,' Dave Moore, executive vice president, of Novo Nordisk's U.S. operations, said in a statement. 'We believe that if even a single patient feels the need to turn to potentially unsafe and unapproved knockoff alternatives, that's one too many.' The company noted in its second-quarter earnings call this month that compounding pharmacies, which are allowed to make versions of medications approved by the U.S. Food and Drug Administration when drugs are in shortage, have affected the sales of its GLP-1 medications. The FDA removed Novo Nordisk's semaglutide-based drugs, Ozempic and Wegovy, along with Eli Lilly's tirzepatide-based drugs, Zepbound and Mounjaro, from the shortage list. Novo Nordisk, however, said compounded versions continue to be sold. By Tami Luhby, CNN

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store